Clinical Trials ·
This study investigates the efficacy and safety of retatrutide in individuals with Type 2 Diabetes and renal impairment. It specifically focuses on participants with inadequate glycemic control while on basal insulin, with or without additional medications such as metformin or sodium-glucose cotransporter-2 (SGLT2) inhibitors.
What this source covers
The study, registered under NCT06297603, aims to compare the effects of retatrutide against a placebo in participants suffering from Type 2 Diabetes and moderate to severe renal impairment. The trial is designed to last approximately 14 months, with participants expected to attend up to 22 visits throughout the study period.
Why it matters for Retatrutide research
This research is significant as it addresses a critical gap in understanding how retatrutide performs in a population that often faces challenges in managing diabetes effectively due to renal complications. By focusing on individuals with inadequate glycemic control on basal insulin, the study may provide insights into the potential benefits of retatrutide in enhancing glycemic outcomes in this vulnerable group.
Key findings or claims
- The study compares retatrutide with a placebo in participants with Type 2 Diabetes.
- Participants have moderate or severe renal impairment.
- Inadequate glycemic control is a primary focus, particularly among those on basal insulin alone or in combination with other medications.
- The trial duration is approximately 14 months, involving up to 22 visits.
- The source does not specify outcomes or results at this stage.
Context and prior work
Retatrutide is part of a new class of medications that target the incretin system, which includes GLP-1 and GIP pathways. Prior research has indicated that incretin-based therapies can improve glycemic control and promote weight loss in individuals with Type 2 Diabetes. However, the specific effects of retatrutide in patients with renal impairment have not been thoroughly explored, making this study a vital addition to the existing literature on GLP-1 receptor agonists and their efficacy in diverse patient populations.
Practical takeaways for researchers
This study highlights the importance of investigating the efficacy of diabetes treatments in populations with comorbid conditions, such as renal impairment. Researchers should consider the implications of renal function on drug metabolism and efficacy when designing future studies. Additionally, findings from this trial could inform clinical practice regarding the management of Type 2 Diabetes in patients with renal challenges.
FAQ
What is the main goal of the TRANSCEND-T2D-3 study?
The main goal is to evaluate the efficacy and safety of retatrutide compared to placebo in participants with Type 2 Diabetes and renal impairment.
How long will the study last?
The study is expected to last approximately 14 months.
Are there any specific medications involved in the study?
Yes, participants may be on basal insulin alone or in combination with metformin and/or SGLT2 inhibitors.
Source: ClinicalTrials.gov · NCT06297603 · published 2025-12-24.